Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
IDH1-Mutated Cancers
Sort By
Newest First
1 / 1
1 / 1
Announcement
Servier Expands Tibsovo (ivosidenib) Program to Study Safety and Efficacy in IDH1-Mutated Hematologic and Solid Tumor Cancers
Servier Pharmaceuticals
PR-01-25-NI-09
Jan 14, 2025
